The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome

Clinica Chimica Acta

Volumn 411, Issue 1-16, 2010, Pages 1084-1089

  Chen, Der Yuan ^a,b,c   Tzang, Bor Show ^c   Chen, Yi Ming ^a,b   Lan, Joung Liang ^a,b,c   Tsai, Chun Chou ^c   Hsu, Tsai Ching ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiphospholid antibody (aPL); Antiphospholipid syndrome (APS); Human parvovirus B19 (B19); Systemic lupus erythematosus (SLE); VP1 unique region protein (VP1u)

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PARVOVIRUS B19; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING;

ABSORPTION; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CAPSID PROTEINS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; PARVOVIRUS B19, HUMAN;

PARVOVIRUS;

EID: 77953261082     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.04.004     Document Type: Article

References (51)

1. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet 1975, 1:72-73.
2. Corcoran A., Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004, 53:459-475.
3. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med 2004, 350:586-597.
4. Anderson S., Momoeda M., Kawase M., Kajigaya S., Young N.S. Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology 1995, 206:626-632.
5. Modrow S., Dorsch S. Antibody responses in parvovirus B19 infected patients. Pathol Biol 2002, 50:326-331.
6. Zádori Z., Szelei J., Lacoste M.C., et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001, 1:291-302.
7. Dorsch S., Liebisch G., Kaufmann B., et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002, 76:2014-2018.
8. Canaan S., Zádori Z., Ghomashchi F., et al. Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem 2004, 279:14,502-14,508.
9. Lu J., Zhi N., Wong S., Brown K.F. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006, 193:582-590.
10. Filippone C., Zhi N., Wong S., et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008, 374:444-452.
11. Musiani M., Manaresi E., Gallinella G., Venturoli S., Zuffi E., Zerbini M. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol 2000, 60:347-352.
12. Bönsch C., Kempf C., Ros C. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol 2008, 82:11,784-11,791.
13. Hsu T.C., Tsay G.J. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40:152-157.
14. Lehmann H.W., von Landenberg P., Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2003, 2:218-223.
15. Von Landenberg P., Modrow S. Human parvovirus B19 infection and antiphospholipid-syndrome: the two sides of one medal?. J Vet Med B Infect Dis Vet Public Health 2005, 52:353-355.
16. Von Landenberg P., Lehmann H.W., Modrow S. Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev 2007, 6:278-285.
17. Loizou S., Cazabon J.K., Walport M.J., Tait D., So A.K. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997, 40:103-108.
18. Chou T.N., Hsu T.C., Chen R.M., Lin L.I., Tsay G.J. Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL). Lupus 2000, 9:551-554.
19. Von Landerberg P., Lehmann H.W., Knoll A., Dorsch S., Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic diseases are associated with parvovirus B19 infection. Arthritis Rheum 2003, 48:1939-1947.
20. Lehmann H.W., Plentz A., Von Landenberg P., Muller-Godeffroy E., Modrow S. Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies. Arthritis Res Ther 2004, 6:R1-R6.
21. Kalt M., Gertner E. Antibodies to beta 2-glycoprotein I and cardiolipin with symptoms suggestive of systemic lupus erythematosus in parvovirus B19 infection. J Rheumatol 2001, 28:2335-2336.
22. Hughes G.R., Harris N.N., Gharavi A.E. The anticardiolipin syndrome. J Rheumatol 1986, 13:486-489.
23. Shoenfeld Y., Gharavi A., Koike T. β2GP-I in the antiphospholipid (Hughes') syndrome-from a cofactor to an autoantigen-from induction to prevention of antiphospholipid syndrome. Lupus 1998, 7:503-506.
24. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
25. Tzang B.S., Tsay G.J., Lee Y.J., Li C., Sun Y.S., Hsu T.C. The association of VP1 unique region protein in acute parvovirus B19 infection and antiphospholipid antibody production. Clin Chim Acta 2007, 378:59-65.
26. Tzang B.S., Lee Y.J., Yang T.P., et al. Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human Parvovirus B19 VP1 unique region protein. Clin Chim Acta 2007, 382:31-36.
27. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999, 42:309-311.
28. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725-1729.
29. National Center for Health Statistics Health promotion and disease prevention, Unites States, 1985. (DHHS pub. No. PHS 88-1591) 1988, US Government Printing Office, Washington, DC, Vital and Health Statistic Series 10: Data from the National Health Survey no. 1630.
30. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
31. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
32. Gallinella G., Zuffi E., Gentilomi G., et al. Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19-correlated diseases. J Med Virol 2003, 71:135-139.
33. Kurtzman G.J., Cohen B.J., Field A.M., Oseas R., Blaese R.M., Young N.S. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989, 84:1114-1123.
34. Saikawa T., Anderson S., Momoeda M., Kajigaya S., Young N.S. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 1993, 67:3004-3009.
35. Musiani M., Manaresi E., Gallinella G., Venturoli S., Zuffi E., Zerbini M. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol 2000, 60:347-352.
36. Lehmann H.W., Plentz A., Von Landenberg P., Küster R.M., Modrow S. Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid antibodies. Clin Rheumatol 2008, 27:333-338.
37. Crowson A.N., Magro C.M., Dawood M.R. A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol 2000, 27:505-515.
38. Hansen K.E., Amason J., Bridges A.J. Autoantibodies and viral illness. Semin Arthritis Rheum 1998, 27:263-271.
39. Dalekos G.N., Kistis K.G., Boumba D.S., et al. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenic link to antiphospholipid syndrome. Eur J Gastroenterol Hepatol 2000, 12:67-74.
40. Uthman I.W., Gharavi A.E. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002, 31:256-263.
41. Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., Meroni P.L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006, 65:2-6.
42. Pierangeli S.S., Harris E.N. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005, 357:17-33.
43. Shoenfeld Y., Blank M., Krause I. The relationship of antiphospholipid antibodies to infections-do they bind to infecting agents or may they even be induced by them?. Clin Exp Rheumatol 2000, 18:431-432.
44. Ballou W.R., Reed J.L., Noble W., Young N.S., Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003, 187:675-678.
45. Saikawa T., Anderson S., Momoeda M., Kajigaya S., Young N.S. Neutralizing linear epitopes of parvovirus B19 cluster in the VP1-unique and VP1-VP2 junction regions. J Virol 1993, 67:3004-3009.
46. Lunardi C., Tiso M., Borgato L., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998, 28:936-948.
47. Blank M., Shoenfeld Y., Cabilly S., Heldman Y., Fridkin M., Katchalski-Katzir E. Prevention of antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999, 96:5164-5168.
48. Mehdi H., Naqvi A., Kambon M.I. A hydrophobic sequence at position 313-316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (β2-GPI) is crucial for cardiolipin binding. Eur J Biochem 2000, 267:1770-1776.
49. Igarashi M., Matsuura E., Igarashi Y., et al. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996, 87:3262-3270.
50. Rayment F.B., Crosdale E., Morris D.J., Pattison J.R., Talbot P., Clare J.J. The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens. J Gen Virol 1990, 71:2665-2672.
51. Blank M., Shoenfeld Y., et al. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clin Immunol 2004, 112:190-199.